Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
50M
-
Number of holders
-
118
-
Total 13F shares, excl. options
-
48.2M
-
Shares change
-
+1.24M
-
Total reported value, excl. options
-
$568M
-
Value change
-
+$14.3M
-
Put/Call ratio
-
1.21
-
Number of buys
-
61
-
Number of sells
-
-59
-
Price
-
$11.78
Significant Holders of KalVista Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (KALV) as of Q2 2024
150 filings reported holding KALV - KalVista Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share as of Q2 2024.
KalVista Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (KALV) has 118 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 48.2M shares
of 50M outstanding shares and own 96.46% of the company stock.
Largest 10 shareholders include VR Adviser, LLC (6.25M shares), TANG CAPITAL MANAGEMENT LLC (4.22M shares), SUVRETTA CAPITAL MANAGEMENT, LLC (4.19M shares), Frazier Life Sciences Management, L.P. (3.69M shares), Capital World Investors (3.23M shares), BlackRock Inc. (2.95M shares), Vestal Point Capital, LP (2.3M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (2.05M shares), VANGUARD GROUP INC (1.99M shares), and Boxer Capital, LLC (1.59M shares).
This table shows the top 118 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.